Skyla IUD Increased The Risk Of Breast Cancer. Our firm is investigating potential lawsuits on behalf of individuals who developed breast cancer after using the Skyla intrauterine device (IUD). Research suggests that use of a levonorgestrel-releasing IUD such as Skyla may increase the risk of developing breast cancer, particularly lobular and ductal breast cancer. If you or someone you know developed breast cancer after using Skyla, contact Parker Waichman LLP today.
Study Links Skyla to Increased Risk of Lobular and Ductal Breast Cancer
A study published in the journal Acta Oncologica in June 2015 found that IUD devices such as Skyla and Mirena are associated with a higher risk for developing breast cancer. The authors investigated levonorgestrel-releasing intrauterine systems (LNG-IUS) to determine whether there was an increased risk of lobular breast cancer. The results revealed that LNG-IUDs such as Skyla and Mirena “is not only related to an excess risk of lobular cancer but also, in contrary to previous assumptions, to an excess risk of ductal breast cancer.”
The study was conducted using data from the national Medical Reimbursement Registry of Finland. Researchers identified women between the ages of 30 and 49 who used levonorgestrel-releasing IUDs to treat or prevent menorrhagia (abnormally heavy menstrual bleeding) between 1994 and 2007. Data from the Finnish Cancer Registry was used to identify women diagnosed with breast cancer before the age of 55 and by the end of 2012.
In a cohort of 93,843 women using LNG-IUS, a total of 2,015 were diagnosed with breast cancer. Use of LNG-IUS was associated with a greater risk of both lobular cancer and ductal breast cancer compared to the general population. Women who purchased the contraceptive at least twice experienced the highest risk; compared to the general female population of similar age, the women were 73 percent likelier to be diagnosed with lobular breast cancer.